Ricroch Agnès, Desachy Louie-David, Penfornis Mateo, Akin Melekşen, Kondić-Špika Ankica, Kuntz Marcel, Miladinović Dragana
Laboratoire Institut Droit, Espaces et Technologies (IDEST), Faculté Jean Monnet, Université Paris-Saclay, Sceaux, France.
AgroParisTech, Université Paris-Saclay, Palaiseau, France.
Front Plant Sci. 2024 Nov 4;15:1452767. doi: 10.3389/fpls.2024.1452767. eCollection 2024.
Field trials (FTs) are a necessary step towards future commercialization of biotech crops and products thereof, whether for research and development or cultivation approval. A total of 187 FTs in 30 countries have been compiled for 2022 and 2023 using a survey and intergovernmental databases. FTs have been classified according to methods, crops and traits. Compiled FTs are mostly conducted by the public sector on eight plant species with improved stress resistance, industrial application, yield, and quality. Regarding genome editing (GenEd), 23 FTs (12% of total) are carried out in 6 countries, on 10 crops. Regulations were examined in 141 countries to discuss why in some countries FTs are not performed, although basic biotech research is carried out. The EU particularly is compared to the rest of the world. Regarding the new proposal in the EU for GenEd product classification, it was found that all recent FTs of such products fall in the category that the EU would consider as 'equivalent to conventional plants' (NGT-1). We also studied current cultivation approvals to highlight differences with crops tested in the field and those may be approved in the future.
田间试验是生物技术作物及其产品未来商业化的必要步骤,无论是用于研发还是种植审批。利用一项调查和政府间数据库,汇总了2022年和2023年30个国家的187项田间试验。田间试验已根据方法、作物和性状进行了分类。汇总的田间试验大多由公共部门针对8种具有改良抗逆性、工业应用、产量和品质的植物物种开展。关于基因组编辑,23项田间试验(占总数的12%)在6个国家针对10种作物进行。对141个国家的法规进行了审查,以探讨为何在一些国家尽管开展了基础生物技术研究,但却未进行田间试验。特别是将欧盟与世界其他地区进行了比较。关于欧盟对基因组编辑产品分类的新提议,发现此类产品最近的所有田间试验都属于欧盟会视为“等同于传统植物”(NGT-1)的类别。我们还研究了当前的种植审批情况,以突出在田间试验的作物与未来可能获批作物之间的差异。